<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059475</url>
  </required_header>
  <id_info>
    <org_study_id>030172</org_study_id>
    <secondary_id>03-C-0172</secondary_id>
    <nct_id>NCT00059475</nct_id>
    <nct_alias>NCT00062218</nct_alias>
  </id_info>
  <brief_title>Peptide Vaccination for Patients at High Risk for Recurrent Melanoma</brief_title>
  <official_title>Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness and side effects of an experimental vaccine to
      prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients
      who have melanoma lesions deep in the skin, in patients who have had positive lymph nodes,
      and in patients who have had surgery for metastatic disease (cancer that has spread beyond
      the primary site). Melanoma tumors produce proteins called glycoprotein 100 (gp100) and
      melanoma-associated antigen recognized by T cells 1 (MART-1). Vaccination with specific
      pieces of these proteins (peptides) may boost the immune system's fight against the cancer.
      The vaccine injections are mixed with an oil-based substance called Montanide ISA-51, which
      is intended to increase the immune response to the peptide.

      Patients 16 years of age and older whose melanoma has been surgically removed and who are
      currently free of disease may be eligible for this study. Candidates will be screened with a
      physical examination and blood and urine tests. An electrocardiogram (EKG), x-rays and other
      imaging studies will be done if recent results are not available. Some candidates may require
      heart tests, such as a cardiac stress test or echocardiogram, or lung function tests. In
      addition, all candidates will be tested for human leukocyte antigen (HLA) tissue type;
      patients must be type human leukocyte antigens (HLA-A)*0201, the type on which this vaccine
      is based.

      Participants will be randomly assigned to receive one of four different vaccines to determine
      which peptides offer the best immunity. Each treatment course consists of two injections of
      the vaccines every 3 weeks for four times. The injections are given under the skin of the
      thigh. After every other treatment course (every 6 months), patients will undergo a series of
      x-rays and scans to look for tumor. The immunizations may continue for up to 12 months as
      long as the melanoma does not return. The injections are given at the National Institutes of
      Health (NIH) Clinical Center. Patients are monitored for 1 hour after each injection and have
      blood tests and a physical examination to look for treatment side effects.

      Patients will be followed with blood tests every 12 weeks to monitor body functions. They
      will also undergo leukapheresis-a procedure to collect white blood cells-before starting
      treatment and about 3 to 4 weeks after the fourth vaccine to evaluate how the vaccines affect
      the action of the immune system cells. For this procedure, blood is drawn through a needle in
      the arm, similar to donating blood. The blood goes through a machine that separates out the
      lymphocytes (white blood cells), and the rest of the blood is returned through a needle in
      the other arm. Some patients may undergo a biopsy-surgical removal of a small piece of tissue
      under local anesthetic-of normal skin and tumor or lymph node tissue to examine the effects
      of the vaccines on the tumor immune cells.

      Patients whose disease returns during the first course of vaccine therapy will have surgery
      to remove the tumor and will continue to receive the vaccine treatment. Patients whose tumor
      returns after completing one course of therapy may receive a substance called interleukin-2
      (IL-2), which can boost immune function against the tumor. interleukin-2 (IL-2) is given
      intravenously (through a small tube placed in a vein) every 8 hours for 4 days. This regimen
      is repeated after 10 to 14 days. Those who respond to interleukin-2 (IL-2) will have a third
      course of treatment after 2 months. Patients whose disease recurs after treatment will be
      taken off the study and will be referred back to their referring physician or to another
      study, if an appropriate one is available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human leukocyte antigens (HLA-A)*0201 positive patients at high risk for recurrence of
      melanoma, or completely resected metastatic melanoma will receive immunization with peptides
      representing human leukocyte antigen (HLA)-restricted T cell epitopes of the melanoma antigen
      recognized by T-cells (MART-1) or glycoprotein 100 (gp100) melanoma antigens emulsified in
      Montanide ISA-51 or Montanide trademark(TM) ISA 51 vegetable grade (VG). Patients will be
      randomized to receive one of three different melanoma antigen recognized by T-cells (MART-1)
      peptides or to receive a combination of a melanoma antigen recognized by T-cells (MART-1)
      peptide plus a glycoprotein 100 (gp100) peptide. This study is designed to evaluate the
      immunologic effects of the different peptide immunizations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic Response Rate</measure>
    <time_frame>11 months</time_frame>
    <description>Immunologic monitoring will be conducted using in vitro sensitization assays. The immunologic response in these assays will be considered positive if at least a two-fold increase in vaccine specific interferon gamma (y-IFN) secretion is seen between post vaccination specimens compared to the pre vaccination specimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 years</time_frame>
    <description>Response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR) (whichever is first) until the first date that recurrent disease is objectively documented. Complete response is the disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>11 months</time_frame>
    <description>Here are the number of participants with adverse events. For details about the adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Adj-2 MART-1: 27-35</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 27-35</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycoprotein 100 (GP100): 209-217 (210M)</intervention_name>
    <arm_group_label>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2 (IL-2)</intervention_name>
    <description>720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).</description>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 27-35</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M</arm_group_label>
    <other_name>Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA 51</intervention_name>
    <arm_group_label>Adj-2 MART-1: 27-35</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 27-35</arm_group_label>
    <arm_group_label>Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)</arm_group_label>
    <arm_group_label>Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)</arm_group_label>
    <arm_group_label>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melanoma antigen recognized by T-cells (MART)-1: 27-35</intervention_name>
    <arm_group_label>Adj-2 MART-1: 27-35</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 27-35</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>27-35 (27L): melanoma antigen recognized by T-cells (MART)-1</intervention_name>
    <arm_group_label>Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)</arm_group_label>
    <arm_group_label>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)</intervention_name>
    <arm_group_label>Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4</arm_group_label>
    <arm_group_label>Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Human leukocyte antigens (HLA-A)*0201 patients, age greater than or equal to 16 years, with
        lesions greater than or equal to 1.5 mm in thickness, or greater than or equal to 1
        positive lymph node, or ulcerated lesions, or local recurrence, or completely resected
        metastatic melanoma, within 6 months of surgical resection will be considered. Patients
        must be clinically disease free at the time of protocol entry as documented by radiologic
        studies within 6 weeks of patient entry.

        Serum creatinine of 2.0 mg/dl or less.

        Total bilirubin 1.6 mg/dl or less, except for patients with Gilbert's Syndrome who must
        have a total bilirubin less than 3.0 mg/dl.

        White blood cell (WBC) 3000/mm^3 or greater.

        Platelet count 90,000 mm^3 or greater.

        Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than three times
        normal.

        Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Patients of both genders must be willing to practice effective birth control during this
        trial because the potential for teratogenic effects are unknown.

        Patients may have had prior adjuvant treatment with immunotherapy, including interferon, or
        may have had treatment for metastatic disease and are now no evidence of disease (NED),
        including chemotherapy or biotherapy, as long as 3 weeks have elapsed since prior systemic
        therapy.

        EXCLUSION CRITERIA:

        Patients will be excluded:

          1. who have ocular or mucosal melanoma.

          2. who are undergoing or have undergone in the past 3 weeks any systemic therapy except
             surgery for their cancer, and must have recovered from any adverse effects of
             treatment prior to entry, other than those that do not have clinical implications,
             e.g. vitiligo, alopecia.

          3. have active systemic infections, autoimmune disease or any known immunodeficiency
             disease.

          4. who require systemic steroid therapy.

          5. who are pregnant or breastfeeding.

          6. who are known to be positive for hepatitis B surface antigen (B(s)AG) or human
             immunodeficiency virus (HIV) antibody.

          7. who have any form of active primary or secondary immunodeficiency or who have not
             recovered immune competence after chemotherapy or radiation therapy.

          8. who have previously been immunized with melanoma antigen recognized by T-cells
             (MART)-1.

          9. who have known hypersensitivity to any of the agents used in this study.

        ELIGIBILITY FOR ADMINISTRATION OF Interleukin-2 (IL-2):

        Patients who develop progressive disease while receiving peptide alone must meet the
        following criteria to be eligible to receive Interleukin-2 (IL-2):

          1. Patients must have measurable metastatic melanoma.

          2. Patients may not have active major medical illnesses such as cardiac ischemia,
             myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary
             disease.

          3. Patients with recent prolonged history of cigarette smoking or symptoms of respiratory
             dysfunction must have a normal pulmonary function test as evidenced by a forced
             expiratory volume 1 (FEV 1) greater than 60% predicted.

          4. Patients with electrocardiogam (EKG) abnormalities, symptoms of cardiac ischemia or
             arrhythmias or age greater than 50 years will have a normal stress cardiac test
             (stress thallium, stress multi-gated acquisition scan (MUGA), dobutamine
             echocardiogram or other stress test).

          5. Patients must be willing to sign a durable power of attorney (DPA).

          6. Serum creatinine of 2.0 mg/dl or less.

          7. Total bilirubin 2.0 mg/dl or less, except in patients with Gilbert's Syndrome who must
             have a total bilirubin less than 3.0 mg/dl.

          8. White blood cell (WBC) 3000/mm^3 or greater.

          9. Platelet count 90,000 mm^3 or greater.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2003-C-0172.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9.</citation>
    <PMID>8170938</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2003</study_first_submitted>
  <study_first_submitted_qc>April 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2003</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg</investigator_full_name>
    <investigator_title>Dr. Steven Rosenberg</investigator_title>
  </responsible_party>
  <keyword>Adjuvant Therapy</keyword>
  <keyword>MART-1 Peptides</keyword>
  <keyword>GP100 Peptide</keyword>
  <keyword>Immunologic Response</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subjects were accrued to this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adj-2 MART-1: 27-35</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
        </group>
        <group group_id="P2">
          <title>Adj-2 HD IL-2 After MART-1: 27-35</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
        </group>
        <group group_id="P3">
          <title>Adj-2 27-35 (27L) MART-1 (Mod9mer) Peptide Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
        </group>
        <group group_id="P4">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 (Mod9mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
        </group>
        <group group_id="P5">
          <title>Adj-2 MART-1: 26-35 (27L) (Mod10mer) Peptide Q3wks x 4</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
        </group>
        <group group_id="P6">
          <title>Adj-2 HD IL-2 After MART-1: 26-35 (27L) (Mod10mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
        </group>
        <group group_id="P7">
          <title>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
        </group>
        <group group_id="P8">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 + gp209-2M</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adj-2 MART-1: 27-35</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
        </group>
        <group group_id="B2">
          <title>Adj-2 HD IL-2 After MART-1: 27-35</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
        </group>
        <group group_id="B3">
          <title>Adj-2 27-35 (27L) MART-1 (Mod9mer) Peptide Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
        </group>
        <group group_id="B4">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 (Mod9mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
        </group>
        <group group_id="B5">
          <title>Adj-2 MART-1: 26-35 (27L) (Mod10mer) Peptide Q3wks x 4</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
        </group>
        <group group_id="B6">
          <title>Adj-2 HD IL-2 After MART-1: 26-35 (27L) (Mod10mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
        </group>
        <group group_id="B7">
          <title>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
        </group>
        <group group_id="B8">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 + gp209-2M</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="34"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="14.9"/>
                    <measurement group_id="B2" value="42.0" spread="8.5"/>
                    <measurement group_id="B3" value="48.5" spread="12.9"/>
                    <measurement group_id="B4" value="52.7" spread="3.8"/>
                    <measurement group_id="B5" value="47.5" spread="13.0"/>
                    <measurement group_id="B6" value="52.0" spread="8.5"/>
                    <measurement group_id="B7" value="44.9" spread="11.4"/>
                    <measurement group_id="B8" value="48.0" spread="8.5"/>
                    <measurement group_id="B9" value="47.55" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response Rate</title>
        <description>Immunologic monitoring will be conducted using in vitro sensitization assays. The immunologic response in these assays will be considered positive if at least a two-fold increase in vaccine specific interferon gamma (y-IFN) secretion is seen between post vaccination specimens compared to the pre vaccination specimens.</description>
        <time_frame>11 months</time_frame>
        <population>The number of participants analyzed and results are correct. We do not have the immunologic response rate data for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Adj-2 MART-1: 27-35</title>
            <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
          </group>
          <group group_id="O2">
            <title>Adj-2 27-35 (27L) MART-1 (Mod9mer) Peptide Q3wks x 4</title>
            <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
          </group>
          <group group_id="O3">
            <title>Adj-2 MART-1: 26-35 (27L) (Mod10mer) Peptide Q3wks x 4</title>
            <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
          </group>
          <group group_id="O4">
            <title>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</title>
            <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Response Rate</title>
          <description>Immunologic monitoring will be conducted using in vitro sensitization assays. The immunologic response in these assays will be considered positive if at least a two-fold increase in vaccine specific interferon gamma (y-IFN) secretion is seen between post vaccination specimens compared to the pre vaccination specimens.</description>
          <population>The number of participants analyzed and results are correct. We do not have the immunologic response rate data for all patients.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For details about the adverse events see the adverse event module.</description>
        <time_frame>11 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adj-2 MART-1: 27-35</title>
            <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
          </group>
          <group group_id="O2">
            <title>Adj-2 HD IL-2 After MART-1: 27-35</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
          </group>
          <group group_id="O3">
            <title>Adj-2 27-35 (27L) MART-1 (Mod9mer) Peptide Q3wks x 4</title>
            <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
          </group>
          <group group_id="O4">
            <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 (Mod9mer)</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
          </group>
          <group group_id="O5">
            <title>Adj-2 MART-1: 26-35 (27L) (Mod10mer) Peptide Q3wks x 4</title>
            <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
          </group>
          <group group_id="O6">
            <title>Adj-2 HD IL-2 After MART-1: 26-35 (27L) (Mod10mer)</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
          </group>
          <group group_id="O7">
            <title>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</title>
            <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
          </group>
          <group group_id="O8">
            <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 + gp209-2M</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For details about the adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR) (whichever is first) until the first date that recurrent disease is objectively documented. Complete response is the disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
        <time_frame>6 years</time_frame>
        <population>The number of participants analyzed and results are correct. We do not have the response rate data for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Adj-2 HD IL-2 After MART-1: 27-35</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
          </group>
          <group group_id="O2">
            <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 (Mod9mer)</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
          </group>
          <group group_id="O3">
            <title>Adj-2 HD IL-2 After MART-1: 26-35 (27L) (Mod10mer)</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
          </group>
          <group group_id="O4">
            <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 + gp209-2M</title>
            <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR) (whichever is first) until the first date that recurrent disease is objectively documented. Complete response is the disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
          <population>The number of participants analyzed and results are correct. We do not have the response rate data for all patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adj-2 MART-1: 27-35</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).</description>
        </group>
        <group group_id="E2">
          <title>Adj-2 HD IL-2 After MART-1: 27-35</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)</description>
        </group>
        <group group_id="E3">
          <title>Adj-2 27-35 (27L) MART-1 (Mod9mer) Peptide Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).</description>
        </group>
        <group group_id="E4">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 (Mod9mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)</description>
        </group>
        <group group_id="E5">
          <title>Adj-2 MART-1: 26-35 (27L) (Mod10mer) Peptide Q3wks x 4</title>
          <description>melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).</description>
        </group>
        <group group_id="E6">
          <title>Adj-2 HD IL-2 After MART-1: 26-35 (27L) (Mod10mer)</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)</description>
        </group>
        <group group_id="E7">
          <title>Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4</title>
          <description>27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).</description>
        </group>
        <group group_id="E8">
          <title>Adj-2 HD IL-2 After 27-35 (27L): MART-1 + gp209-2M</title>
          <description>High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anticipated Dose Limiting Toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="5" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Low urine output</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="90" subjects_affected="31" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="66" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="94" subjects_affected="32" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="89" subjects_affected="29" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven A. Rosenberg, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-6375</phone>
      <email>nciirbadmin@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

